About Us

NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.

Clinical Stage Products

Lynovex NM001 (from NovaBiotics' Cysteamine platform) is a novel, highly differentiated therapy for the treatment of CF-associated lung disease and is intended for use alongside existing standard of care CF therapy to treat all CF genotypes (it is not a mutation-specific intervention). Orphan drug designation has been granted for Lynovex in the US and Europe. NovaBiotics is developing two different formulations of Lynovex NM001; an oral presentation for acute infectious exacerbations and an inhaled form for longer term maintenance and symptom management.

Novexatin is a step change in the topical treatment of nail fungus (onychomycosis). Based on the results of studies to date, Novexatin is the first topical agent with the potential to resolve infection and deliver rapid cosmetic benefits with very short duration of treatment vs. 48 weeks for currently available topical treatments.

Preclinical Pipeline & Proprietary Antimicrobial Peptide Platform

NovaBiotics is developing its robust pipeline of antifungal and antibacterial candidates including NP339 and NP432 derived from its proprietary antimicrobial peptide technology platform. This rational drug design approach enables the development of smaller, simpler and therapeutically viable AMP based on endogenous AMP; the cornerstone of the body’s host defence against microbes. The platform is validated by Novexatin and also NP108, a polypeptide currently in clinical development with NovaBiotics' veterinary health pharmaceutical partner for the treatment of bovine mastitis.

Intellectual Assets & Provenance

NovaBiotics has a strong portfolio of granted and pending patents which are wholly owned by the Company. NovaBiotics was founded by our CEO, Dr. Deborah O’Neil in 2004 with the goal of fully developing and realizing the therapeutic and commercial potential of antimicrobial peptides. NovaBiotics is a privately held company, based in Aberdeen, UK & Boston, MA, U.S.